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ABSTRACT 
 
Background and Aims: Mast cells (MCs) are tissue-dwelling effector cells of innate and adaptive 
immunity that differentiate in peripheral tissues from committed circulating progenitor cells of bone 
marrow origin. Human MCs are conventionally classified into two major subtypes based on their 
neutral protease content, namely the MCT, which contain only tryptase and the MCTC, which contain 
both tryptase and chymase, as well as carboxypeptidase A3 and cathepsin G. Granzyme B has been 
identified in cultured human MCs and in MCs of human skin. In vitro studies have helped trace 
factors that regulate human MC development and have provided a powerful method for studying 
neutral protease expression during MC development. However, inconsistent information from these 
studies has made it impossible to establish a consistent concept of what causes MCs to develop into 
MCT and MCTC: are they two committed subtypes deriving from two distinct progenitors with 
irreversibly predetermined protease phenotype, or are they functional states that MCs assume under 
the influence of the local microenvironment? Previous findings of human tissue MCs further imply 
that the phenotypic heterogeneity of human MCs may be greater than initially suggested. However, 
an understanding of the complexity of the phenotypic heterogeneity of human MCs, and to what 
extent this heterogeneity is intrinsically variable, has been hindered. This is because virtually all 
studies describing the relationship of human MC development and protease expression have 
focused on the expression of tryptase and/or chymase, whereas the expressions of carboxypeptidase 
A3, cathepsin G, and granzyme B by human MCs have not been fully considered. The aim of the 
present Master's thesis was to clarify the contradictions on human MC phenotypes and their 
development by studying how MCs derived from their circulating progenitors express the various 
neutral proteases during their development. 
Methods: MCs were generated from human peripheral blood-derived CD34
+
 progenitors under the 
influence of Kit ligand and sequentially added cytokines according to a previously published 
method. The protease expressions of tryptase, chymase, carboxypeptidase A3, cathepsin G, and 
granzyme B were investigated on a weekly basis during MC development by flow cytometry and 
quantitative PCR. Furthermore, immunostainings of the proteases were performed for 
immunofluorescence microscopy. 
Results: All investigated proteases were detected in the developing MCs at week 1 of culture and 
were increasingly expressed beyond that time. By the end of week 6, a single homogeneous 
population of cells expressing all the investigated proteases was observed. 
Conclusion: The data of the present study suggest that human MCs derive from a common 
circulating progenitor cell, which has the potential to express the full complement of the 
investigated proteases. Thus, the heterogeneity of human MC protease phenotypes reflects 
microenvironmental regulation of protease expression, rather than the existence of distinct 
progenitor cells with precommitted protease phenotypes. 
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TIIVISTELMÄ 
 
Tausta ja Tavoitteet: Syöttösolut ovat ihmisen synnynnäisen ja hankitun immuniteetin keskeisiä 
toimijasoluja, jotka erilaistuvat kudoksissa luuytimestä peräisin olevista, verenkierrossa kiertävistä 
esiastesoluista. Ihmisen syöttösolut jaetaan perinteisesti kahteen alatyyppiin niiden sisältämien 
neutraaliproteaasien perusteella. Nämä ovat MCT syöttösolu, joka sisältää ainoastaan tryptaasia ja 
MCTC syöttösolu, joka sisältää tryptaasia ja kymaasia. Jälkimmäiseen alatyyppiin kuuluvat 
syöttösolut sisältävät myös karboksipeptidaasi A3:a ja katepsiini G:tä. Lisäksi ihmisen viljellyt ja 
ihosta eristetyt syöttösolut ilmentävät grantsyymi B:tä. Ihmisen syöttösolujen erilaistaminen 
viljelyolosuhteissa on mahdollistanut neutraaliproteaasien ilmentymisen tutkimisen syöttösolujen 
erilaistumisen ja kasvun aikana. Tästä huolimatta on epäselvää, ovatko MCT ja MCTC peräisin 
kahdesta eri kehityslinjasta vai ovatko ne ennemminkin syöttösolun toiminnallisia tiloja, jotka 
määräytyvät ympärillä vallitsevien olosuhteiden mukaan. Viime vuosien löydökset viittaavat lisäksi 
siihen, että ihmisen syöttösolujen proteaasi-ilmiasujen kirjo on luultua monimuotoisempaa. Se, 
kuinka kirjavaa tämä monimuotoisuus on, ja missä määrin se on synnynnäisesti vaihtelevaa, on 
kuitenkin epäselvää. Tämä johtuu pääosin siitä, että valtaosa tutkimuksista on keskittynyt vain 
tryptaasin ja/tai kymaasin ilmentymiseen, kun taas muiden neutraaliproteaasien ilmentymistä ei ole 
juurikaan tutkittu. Tässä tutkimuksessa seurattiin kaikkien tunnettujen ihmisen 
syöttösoluproteaasien ilmentymistä viljeltyjen syöttösolujen erilaistumisen ja kasvun aikana. 
Tavoitteena oli selventää nykyistä käsitystä ihmisen syöttösolujen proteaasi-ilmiasujen 
monimuotoisuudesta ja niistä tekijöistä, jotka ovat tämän monimuotoisuuden takana.  
Menetelmät: Syöttösolut erilaistettiin viljelemällä verenkierrosta eristettyjä CD34
+
 esiastesoluja 
tärkeimmän syöttösolujen kasvua edistävän kasvutekijän, Kit ligandin ja jaksoittain lisättyjen 
sytokiinien, interleukiini (IL)-3:n, IL-9:n ja IL-6:n kanssa. Solujen erilaistumisen ja kasvun aikana 
tryptaasin, kymaasin, karboksipeptidaasi A3:n, katepsiini G:n ja grantsyymi B:n ilmentymistä 
tutkittiin viikoittain kvantitatiivisella PCR:lla ja virtaussytometrialla.  Lisäksi tehtiin 
immunovärjäyksiä mikroskopointia varten. 
Tulokset: Kaikki tutkitut proteaasit tunnistettiin syöttösolujen kehittymisen aikana sekä mRNA että 
proteiinitasolla jo ensimmäisen viljelyviikon jälkeen. Proteaasien ilmentymistasot nousivat viljelyn 
edetessä, ja kuuden viikon jälkeen kaikki syöttösolut ilmensivät tutkittuja proteaaseja. Yhdenkään 
proteaasin kohdalla ei havaittu erillisiä proteaasipositiivisia tai proteaasinegatiivisia 
alapopulaatioita, vaan jokaisessa tutkitussa aikapisteessä havaittiin yksi syöttösolupopulaatio, joka 
ilmensi vaihtelevalla tasolla tutkittua proteaasia.  
Yhteenveto: Tämän tutkimuksen tulokset viittaavat siihen, että ihmisen syöttösolut ovat peräsin 
yhteisestä esiastesolusta, joka pystyy ilmentämään kaikkia tutkittuja neutraaliporteaaseja. 
Syöttösolujen proteaasi-ilmiasujen heterogeenisyys on seurausta paikallisessa kudosympäristössä 
olevista tekijöistä, kuten sytokiineista, joilla on kyky säädellä proteaasien ilmentymistasoja.  
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1. INTRODUCTION 
 
Mast cells (MCs) are tissue-dwelling multifunctional effector cells best known for their pivotal role 
in IgE-mediated allergic disorders (Galli & Tsai, 2012). The hallmark of tissue MCs is their 
numerous cytoplasmic secretory granules, which store a wide variety of biologically active 
mediators, most importantly histamine, heparin proteoglycan, and various neutral proteases 
(Metcalfe et al., 1997). By releasing these, and also other mediators, such as various cytokines, 
chemokines and lipid mediators upon activation, MCs can elicit various anti-inflammatory and pro-
inflammatory functions in the body (Galli et al., 2008). MCs have been identified in all vertebrate 
classes, however, MCs in different species, as well as at distinct anatomical sites display marked 
plasticity in their morphological, histochemical, biochemical, and functional characteristics and 
phenotypically distinct subtypes of MCs can be found within the tissues of humans and other 
species (Huff & Lanz, 1997; Metcalfe et al., 1997). Human MCs are conventionally classified into 
two distinct subtypes based on their neutral protease composition, the MCT containing exclusively 
tryptase and the MCTC containing both tryptase and chymase, as well as carboxypeptidase A3 and 
cathepsin G (Irani et al., 1986; Irani et al., 1989; Schechter et al., 1990; Irani et al., 1991). Cultured 
human MCs and MCs of human skin also contain granzyme B (Strik et al., 2007). 
 
Human MCs derive from committed circulating progenitor cells of bone marrow origin and 
differentiate in peripheral tissues under the influence of the local microenvironment (Okayama & 
Kawakami, 2006). MCs are present in virtually all vascularized tissues, however, quite different 
proportions of MCTC to MCT have been reported within various tissues (Weidner & Austen, 1993; 
Irani & Schwartz, 1994), and specific functions for MCTC and MCT have been suggested (McNeil & 
Gotis-Graham, 2000). In vitro studies have provided a powerful tool for the investigation of the 
relationship between MC development and protease expression however, the developmental 
pathway leading to MCT and MCTC has remained a subject of conflicting evidence. Furthermore, 
previous findings of MCs within human tissues imply that the phenotypic diversity of the human 
MC is greater than initially suggested (Weidner & Austen, 1993; Abonia et al., 2010; Dougherty et 
al., 2010). 
 
This Master's thesis is based on a published piece of work, which provided the first study to 
investigate the expression of various human MC neutral proteases, namely tryptase, chymase, 
CPA3, cathepsin G, and granzyme B during the development of human MCs from their progenitors 
present in the adult circulating blood (Maaninka et al., 2013).  
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2. REVIEW OF THE LITERATURE 
 
2.1. Mast cells —Historical perspective 
 
The German pathologist Friedrich von Recklinghausen first described MCs cells in 1863 when he 
found these granular cells in the mesentery of the frog. However, Paul Ehrlich, the German 
scientist, who received the Nobel Prize for his contributions to immunology, is credited with the 
discovery of MCs, as we know them today. Ehrlich discovered MCs in 1877, while he was still a 
medical student at Freiburg University. The discovery was based on the specific staining 
characteristics of MC cytoplasmic granules. Ehrlich noticed that when connective tissues were 
stained with aniline blue, certain cells dyed red. After precise dissection, he noticed that the stained 
cells were full of cytoplasmic granules that had turned from a blue to a reddish color, a phenomenon 
referred to as metachromasia (Fig. 1). Ehrlich believed that the MC granules were the result of 
overfeeding, and named the cells Mastzellen based on "mästen" in German, which refers to feeding 
(Schwartz & Huff, 1998). In addition to MCs, which he found associated with blood vessels, 
inflamed tissues, and nerves, Ehrlich described basophils as metachromatic cells that circulated in 
the blood. Based on his pioneering studies on blood cell polychromatophilia, which led to the 
systematic and fundamental classification of blood cells still in clinical use, Ehrlich is generally 
considered the founder of hematology. 
 
 
 
 
 
 
 
 
Figure 1. Cultured human MC displaying metachromatic staining. Human MCs were cultured 
for 9 weeks and stained with toluidine blue (Lappalainen et al., 2007). 
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Since the initial description of Ehrlich, MCs have been identified by their metachromatic staining 
properties. The metachromasia exhibit by MCs is based on interaction of basic dyes such as Alcian 
blue with the highly sulfated glycosaminoglycans (GAG), notably heparin, within MC secretory 
granules (Metcalfe et al., 1997). The presence of heparin within MCs was initially described in the 
1930 and was confirmed in the 1960s by a study showing that heparin is a main granule component 
of rat serosal MCs (Lagunoff et al., 1964; Rönnberg et al., 2012). Soon after that Enerbäck, 
however, noticed that tissue MCs in rats exhibit differences in fixation and dye-binding properties, 
an observation that provided the first evidence of MC heterogeneity (Enerbäck, 1966). 
Heterogeneity between tissue MCs was confirmed and extended by immunohistochemcial studies 
of Woodbury and Miller by showing that the MCs present in the peritoneal cavity of rat differed 
from those in the jejunum in the terms of their expression of the chymase-like serine proteases they 
designated as rat mast cell protease (rMCP)-1 and rMCP-2, respectively (Woodbury et al., 1978; 
Gibson & Miller, 1986). In support of these histochemistry and protease data, it was shown that the 
two populations of rat MCs, designated as connetive tissue MCs (CTMC) and mucosal MCs 
(MMC) stored serglycin proteoglycans in their secretory granules that contained different GAGs 
(Metcalfe et al., 1997). This finding explained the differences in histochemical staining properties 
initially described by Enerbäck by showing that the differences in fixation and dye-binding 
properties of rodent MC subtypes is causally related to the presence of heparin only in the CTMC, 
whereas both subtypes contain chondroitin sulfates  (Huff & Lanz, 1997).   
 
By analogy to rodents, two major MC subtypes have been described within human tissues. In 
contrast to rodents, all mature human MCs contain heparin, and thus heparin-dependent fixation and 
histochemical procedures used in rodents cannot be used to distinguish human MCs (Metcalfe et al., 
1997). Instead, human MCs are divided into two distinct subtypes based on their neutral protease 
composition. The concept of the existence within human tissues of two distinct MC subtypes 
distinguishable by their neutral protease composition is based on immunohistochemical studies of 
Schwartz and his group in the 1980s. By using newly developed antibodies against tryptase and 
chymase, Schwartz and coworkers found that certain MCs stained positive for tryptase only, 
whereas others stained positive for both tryptase and chymase. Based on the absence or presence of 
chymase these MCs were named MCT and MCTC to indicate an MC containing tryptase only and a 
MC containing both tryptase and chymase respectively (Irani et al., 1986; Irani et al., 1989). 
However, this nomenclature is not optimal because further studies demonstrated that MCTC also 
contain the neutral proteases carboxypeptidase A3 (CPA3) and cathepsin G (Schechter et al., 1990; 
Irani et al., 1991). Besides MCT and MCTC, two additional human MC phenotypes, namely MCC 
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indicating an MC containing chymase only and an MC containing tryptase and CPA3 but not 
chymase have been identified within human tissues (Weidner & Austen, 1993; Abonia et al., 2010; 
Dougherty et al., 2010). However, the existence of MCC has remained a subject of conflicting 
evidence, since many authors have failed to detect it (Irani et al., 1989; Tetlow & Woolley, 1995; 
Gotis-Graham & McNeil, 1997). Furthermore, an MC containing tryptase and CPA3 has been 
relatively recently identified (in 2010) within human tissues (Abonia et al., 2010; Dougherty et al., 
2010), and thus its presence has not been fully established.  
 
 
2.2. Mast cell neutral proteases 
 
Neutral proteases are proteolytic enzymes having a neutral-to-slightly-basic pH optimum, and are 
the main protein constituents of the secretory granules of human MCs. Apart from one, the CPA3, 
which is a zinc-containing exopeptidase of the metalloproteinase family, all MC neutral proteases 
are serine proteases characterized by an active site serine residue. 
 
There are remarkable variations in the composition of neutral proteases within the MCs between 
different species, especially between human and rodent species. Neutral protease activity was first 
described in the MCs of humans, dogs, rats, mice, and rabbits in the early 1950s by a histochemical 
technique involving cleavage of the chromogenic substrate 3-chloroacetoxy-2-napthoic acid anilide 
(Gomori, 1953). A couple of years later, this activity was characterized as chymotrypsin-like 
because it hydrolyzed acetyl ethyl esters of aromatic but not basic amino acids (Benditt & Arase, 
1959). In the 1960s, using other substrate-based techniques, human skin MCs were reported to 
contain substantial levels of trypsin-like enzyme activity. However, it was a couple of decades until 
tryptase and chymase responsible for trypsin-like and chymotrypsin-like enzyme activities, 
respectively, were first isolated and characterized (Schwartz et al., 1981; Schechter et al., 1983). To 
date at least six MC-specific neutral proteases, namely four tryptases (α-, β-, γ-, and δ-tryptases), 
chymase, and CPA3, as well as two additional serine proteases, cathepsin G and granzyme B, which 
are classically related to neutrophils, and to cytotoxic T-cells and natural killer cells, respectively, 
have been identified in human MCs (Schechter et al., 1983; Goldstein et al., 1987; Schechter et al., 
1990; Caughey, 2007; Strik et al., 2007). A novel human MC protease, granzyme H has been 
reported in human MCs, but it was characterized after the experimental part of this Thesis was 
completed (Rönnberg et al., 2014).  
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2.2.1. Human mast cell neutral proteases 
 
2.2.1.1. Tryptase 
Tryptase is present in most, if not all, human MCs (Metcalfe et al., 1997). Tryptase has trypsin-like 
cleavage specificity, as it cleaves protein substrates at the C-terminal side of arginine and lysine 
residues (Schwartz et al., 1981; Tanaka et al., 1983). However, unlike the many tryptic peptidases 
associated with digestion, hemostasis, clot lysis, and complement activation, tryptase is highly 
selective regarding its peptide and protein targets (Schwartz et al., 1981; Tanaka et al., 1983), which 
underscores its unique position in the hierarchy of peptidases belonging to the trypsin family. MC 
tryptase has several unique features, one of the most remarkable ones being its organization into a 
tetrameric state with the active sites oriented toward a narrow central pore, and its consequent 
resistance to endogenous macromolecular protease inhibitors, such as serpins and α2-macroglobulin 
(Caughey, 1997). 
 
The human MC tryptase locus resides on chromosome 16p13.3 and spans approximately 1.6 Mb 
(Pallaoro et al., 1999). To date, four MC tryptase genes (TPSAB1, TPSB2, TPSD1, and TPSG1) 
plus various pseudogenes have been identified in humans (Pallaoro et al., 1999; Caughey et al., 
2000). These fall into two major groups: the soluble α-, β-, and δ-tryptases and the membrane-
anchored γ-tryptase, also known as transmembrane tryptase or TMT (Pallaoro et al., 1999). Of 
these, the β-tryptase appears to be the main form stored in human MC granules, and it occurs in 
three almost identical forms: βI, βII, and βIII (Miller et al., 1990; Vanderslice et al., 1990). 
 
Among the α-tryptases, two very similar forms have been identified in humans: αI and αII (Miller et 
al., 1989; Pallaoro et al., 1999). However, the activity of human α-tryptase is extremely low 
compared with β-tryptase, which is partly due to the amino acid substitution of glycine for 
asparagine at the position 216 of the substrate-binding pocket (Huang et al., 1999). It has been 
suggested that, in contrast to β-tryptase, which is stored in the secretory granules and not released 
unless the MCs have been challenged by a degranulating stimulus, α-tryptase is  constitutively 
released via a selective pathway (Schwartz et al., 1995). From δ-tryptase, two nearly identical forms 
(δI and δII) have been identified (Wang et al., 2002). However, the activity of δ-tryptase is also 
much lower than that of β-tryptase, which is mainly due to a premature stop codon that results in a 
truncated protein and affects the substrate specificity of δ-tryptase significantly (Wang et al., 2002). 
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Finally, two different forms of the human transmembrane tryptase (γ-tryptase) have been identified: 
γI and γII (Caughey et al., 2000). The γ-tryptases contain an extended hydrophobic C-terminal 
domain followed by a small cytoplasmic tail, are anchored in either the plasma membrane or the 
secretory granule membrane, and only act locally upon MC activation (Caughey et al., 2000). 
 
2.2.1.2. Chymase 
In humans, the major chymotryptic protease, as defined by its preference for cleaving peptide and 
protein substrates at the C-terminal site of aromatic amino acids, such as phenylalanine, tyrosine, 
and tryptophan, is the neutral serine protease chymase (Powers et al., 1985; Caughey, 2007). Only 
one chymase gene (CMA1) has been found in humans (Caughey et al., 1993), and  human MCs are 
conventionally divided into two distinct subtypes, the MCTC and MCT, based on the presence or 
absence, respectively, of this chymase within their granules. Human MC chymase is located on 
chromosome 14q11.2 (Caughey et al., 1993) at the end of a small cluster of four genes covering 
approximately 130 kb. This cluster also contains the cathepsin G gene (CTSG) and the granzyme H 
and B genes (GZMH and GZMB respectively) (Caughey et al., 1993). The human chymase is active 
in its monomeric form (Pejler et al., 2007) and has more destructive potential than tryptase, given 
that it can cleave a fairly wide variety of peptide and protein targets (Caughey, 2007). Befitting its 
greater destructive potential, chymase is more susceptible to inhibition by circulating and 
extravascular anti-peptidases, including serpins and α2-macroglobilin, and is thus quickly inhibited 
after release, although some protection against inhibition is gained by tight binding to co-released 
proteoglycans, such as heparin (Lindstedt et al., 2001; Caughey, 2007). 
 
2.2.1.3. Carboxypeptidase A3 
Human CPA3 is a zinc-dependent metalloexoprotease that belongs to the carboxypeptidase (CP) 
A/B family. As indicated by the letter "A" in its name, CPA3 has a CPA-like cleavage specificity, 
i.e., it prefers cleaving peptide and ester bonds at the amino side of the C-terminal aromatic amino 
acids (Goldstein et al., 1989). Human CPA3 is encoded by a single gene (CPA3), which situates on 
chromosome 3q24 (indicated by number 3 in its name) and spans over 32 kb (Pejler et al., 2007). 
The expression of CPA3 is suggested to be MC-specific (Li et al., 1998) and it has been identified 
in the MCTC and in MCs containing tryptase and CPA3 but not chymase (Goldstein et al., 1989; 
Abonia et al., 2010; Dougherty et al., 2010). Despite having a CPA-like substrate-binding pocket 
and enzyme activity, CPA3 is structurally similar to bovine and human pancreatic CPB, which 
indicates its uniqueness among CPs (Goldstein et al., 1989; Reynolds et al., 1992). 
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2.2.1.4. Cathepsin G 
Human cathepsin G is a serine protease that belongs to the cathepsin class of enzymes. Unlike 
tryptase, chymase, and CPA3, which are considered MC-specific proteases, expression of cathepsin 
G is classically related to neutrophils (Korkmaz et al., 2008). In human MCs, the expression of 
cathepsin G is mainly restricted to the MCTC type (Schechter et al., 1990). Only one cathepsin G 
gene (CTSG) has been identified in humans, and it is located within a cluster of four genes on 
chromosome 14q11.2 (Caughey et al., 1993). Similar to chymase, cathepsin G has chymotrypsin-
like activity, but cathepsin G is generally a weaker enzyme than chymase in terms of its destructive 
potential, and it has a broader peptidase specificity; that is, it exhibits the unusual property of 
having both chymotryptic and tryptic activity (Caughey, 2007). 
 
2.2.1.5. Granzyme B 
The presence of granzyme B, a member of a family of death-inducing serine proteases classically 
related to granule components of cytotoxic T lymphocytes and natural killer cells (Lieberman, 
2003), was identified within human MCs in 2007 (Strik et al., 2007). It was reported to be present in 
cultured human MCs and MCs of human skin. Five granzyme subtypes have been identified in 
humans (A, B, H, K, and M) (Barry & Bleackley, 2002), and granzyme B is the most characterized 
of all (Ngan et al., 2009). Granzyme B is a caspase-like serine protease that cleaves substrates at the 
carboxyl side of acidic residues, particularly aspartic acid (Fan & Zhang, 2005). The granzyme B of 
lymphocytes and NK cells is a pro-apoptotic intracellular protease, which requires perforin to form 
pores in the plasma membrane of the target cells to help its entry into intracellular compartments  
(Fan & Zhang, 2005). Unlike lymphocytes, MCs do not store perforin in their secretory granules 
(Pardo et al., 2007), which suggests a unique function of MC-derived granzyme B. However, the 
extracellular effects of this enzyme are not well understood (Froelich et al., 2009). 
 
 
2.2.2. Rat and mouse mast cell neutral proteases 
 
Most of our knowledge about the biology of MC neutral proteases is based on studies using 
experimental animals, most notably rat and mouse. However, there appear to be remarkable 
differences in the neutral proteases present within MCs of human and rodent species, especially 
mice, which can store a substantially larger number of different proteases than humans. In contrast 
to humans, who express a single chymase, several chymase forms can be found within the MCs of 
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Table 1. Human, mouse, and rat MC proteases 
MC Protease Preferential subtype expressed Homologues 
MC chymases   
hChymase 1  MCTC, MCC mMCP-5, rMCP-5 
mMCP-1 MMC rMCP-4 
mMCP-2 MMC rMCP-2 
mMCP-4 CTMC rMCP-1 
mMCP-5 CTMC rMCP-5 
mMCP-8 Data not available rMCP-8, rMCP-9, rMCP-10,  
mMCP-9 CTMC rMCP-3 
rMCP-1 CTMC mMCP-4 
rMCP-2 MMC mMCP-2 
rMCP-3 MMC mMCP-9 
rMCP-4 MMC mMCP-1 
rMCP-5 CTMC mMCP-5 
rMCP-8 MMC mMCP-8 
rMCP-9 MMC  
rMCP-10 MMC  
MC tryptases   
hTryptase αI/βI MCT, MCTC, MC containing tryptase and CPA3 mMCP-6, rMCP-6 
hTryptase βII/βIII MCT, MCTC, MC containing tryptase and CPA3 mMCP-6, rMCP-6 
hTryptase δ MCT, MCTC, MC containing tryptase and CPA3 mMCP-7, rMCP-7 
hTMT/Tryptase γ MCT, MCTC, MC containing tryptase and CPA3 mTMT, rTMT 
rTMT CTMC mTMT, hTMT/Tryptase γ 
rMCP-6 CTMC mMCP-6, hTryptase αI/ βI, hTryptase βII/βIII 
rMCP-7 CTMC mMCP-7, hTryptase δ 
rMCP-11 Data not available mMCP-11 
mTMT Data not available rTMT, hTMT/Tryptase γ 
mMCP-6 CTMC rMCP-6, hTryptase αI/ βI, hTryptase βII/βIII 
mMCP-7 CTMC rMCP-7, hTryptase δ 
mMCP-11 Data not available rMCP-11 
CPA   
hCPA MCTC, MC containing tryptase and CPA3 rCPA, mCPA 
rCPA CTMC mCPA, hCPA 
mCPA CTMC rCPA, hCPA 
Cathepsin G   
hCathepsin G MCTC  
mCathepsin G Data not available  
Granzymes   
hGranzyme B Cultured human MCs, MCs of human skin  
hGranzyme H Cultured human MCs, MCs of human skin  
mGranzyme B Data not available  
mGranzyme D BMMC, PCMC  
Neuropsin   
mNeuropsin BMMC  
Data from (Weidner & Austen, 1993; Lunderius & Hellman, 2001; Pardo et al., 2007; Pejler et al., 2007; 
Stevens & Adachi, 2007; Strik et al., 2007; Abonia et al., 2010; Dougherty et al., 2010; Rönnberg et al., 
2013). BMMC; Bone marrow-derived MC, PCMC; Peritoneal cell-derived MC 
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rats and mice. Furthermore, tryptase expression in rodents appears to be restricted to MC population 
residing at connective tissues, whereas in humans, tryptase (at least β-tryptase) is found in most, if 
not all, MCs irrespective of their tissue localization. Current nomenclature decribes MC chymases 
and tryptases in rat and mouse as rat mast cell proteases (rMCPs) and mouse mast cell proteases 
(mMCPs), respectively. Table 1 summarizes neutral protease expression in humans, rats, and mice.  
 
 
2.3. Tissue distribution and function of human mast cell subtypes 
 
Quite different proportions of MCT and MCTC subpopulations have been reported in various human 
tissues by different groups of investigators. However, there appear to be some rules governing the 
tissue distribution of the MC subtypes. In histologically normal human tissues, MCT is the primary 
subtype at the mucosal surfaces of the respiratory and gastrointestinal tracts, such as in the lung, 
particularly the alveoli, and the small intestinal mucosa, whereas MCTC cells are the predominant 
subtype found in the skin, synovium, and gastrointestinal submucosa (Irani et al., 1986; Irani et al., 
1989). Although a particular MC subtype appears to predominate in a particular tissue, a fraction of 
the other subtype is also usually present (Table 2), and the relative abundances of MCT and MCTC 
subtypes may change with inflammation and other disease processes (Table 3). Accordingly, MC 
subtype designation based exclusively on tissue location is not justified. 
 
The localization of MCs at sites close to the external milieu reflects their role as important sentinels 
of the body. MCs can contribute to many processes of both innate and adaptive immunity and can 
have both protective and pathogenic roles (Galli & Tsai, 2010). MCs mediate their effector 
functions by releasing the various neutral proteases and other mediators upon activation by an 
appropriate stimulus, such as the classical allergic activation caused by crosslinking of receptor-
bound IgE by an IgE-specific antigen or allergen (Metcalfe et al., 1997). The process of protease 
exocytosis that results from the FcεRI signaling pathway is called degranulation (Fig. 2; right 
panel). 
 
Several studies have begun to address the presence of distinct MC subtypes in various human 
diseases. For example, MC hyperplasia has been noted in rheumatoid synovium at sites of cartilage 
erosion (Bromley et al., 1984; Tetlow & Woolley, 1995). In the rheumatoid joint, MCTC appear to 
be associated with areas of dense fibrosis, whereas variable ratios of both MCT and MCTC cells have  
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been found at sites of active inflammation (Gotis-Graham & McNeil, 1997). This observation 
suggests a function for MCT in inflammatory events, whereas  MCTC appears to be more relevant in 
processes of tissue remodeling (McNeil & Gotis-Graham, 2000). However, due to lack of strong 
Table 2. Distribution of MCT, MCTC, and MCC in normal human tissues 
Tissue % MCT % MCTC % MCC 
Skin <1 >99  
Lung    
 Alveoli 91/93 8/7 1/- 
 Bronchi 78 10 12 
 Bronchial epithelium 100 0 - 
 Bronchial subepithelium 75 25 - 
Axillary lymph nodes 1 97 2 
Breast parenchyma 1 99 0 
Stomach    
 Mucosa 52 39 9 
 Submucosa 0 73 27 
Small intestine    
 Mucosa 65/81 31/19 4/- 
 Submucosa 0/23 76/77 24/- 
Colon    
 Mucosa 53 37 10 
 Submucosa 0 96 4 
Nasal mucosa 66 34 - 
Conjunctiva 5 95 - 
Synovium
 17/34 83/66 -/- 
Heart 10 90 - 
Kidney 65
 
35 - 
Uterus     
 Endometrium 84 16 - 
 Inner myometrium 48 52 - 
 Outer myometrium 10 90 - 
 Cervix 40 60 - 
Data from (Weidner & Austen, 1993; Irani & Schwartz, 1994; Sperr et al., 1994; 
Mori et al., 1997; Buckley et al., 1998; Gotis-Graham et al., 1998; Yamada et al., 
2001). Data are expressed as mean. -, Data not available; /, different values given by 
the authors. 
 
 
 Table 3. Relative abundances of MCT and MCTC in normal and diseased human tissues 
MC 
subtype 
Synovium  Kidney Carotid Artery 
 Normal Early 
RA 
Late 
RA 
Normal Rejected 
nephrect. 
specimens 
Rejected 
biopsy 
specimens 
Normal Early 
lesion 
Advanced 
lesion 
MCT 17% 72% 37% 65% 65% 71% 10-20% 30-40% 0-10% 
MCTC 83% 28% 63% 35% 35% 29% 80-90% 60-70% 90-100% 
RA; Rheumatoid arthritis; Data from (Jeziorska et al., 1997; Gotis-Graham et al., 1998; Yamada et al., 
2001) 
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experimental evidence, the question how and why an MC develops into MCT and MCTC remains a 
matter of debate. 
 
 
 
 
 
 
 
Figure 2. Scanning electron micrographs of resting and degranulating rat serosal MCs. Under 
normal conditions, MCs are found in tissues in their resting state storing the various neutral 
proteases in their cytoplasmic granules (Left panel). However, upon activation of an appropriate 
stimulus, such as crosslinking of receptor-bound IgE by an antigen, MCs acutely exocytose their 
preformed mediators in a process called degranulation (Right panel). Whereas histamine and other 
soluble mediators diffuse away, a fraction of the exocytosed neutral proteases remain bound to 
heparin, forming a proteolytically active granule remnant (Kokkonen & Kovanen, 1990). 
 
 
2.4. Mast cell development 
 
The origin of tissue MCs remained unclear for a long time; in the decades after the discovery of 
MCs, they were incorrectly identified as deriving from T cells, plasma cells, monocytes, basophils, 
fibroblasts, mesenchymal cells, and even from endothelial cells (Burnet, 1977; Zucker-Franklin, 
1980; Czarnetzki et al., 1982; Metcalfe et al., 1997; Schwartz & Huff, 1998). However, to date, it is 
clear that MCs, like basophils and other blood cells, derive from hematopoietic stem cells in the 
bone marrow. MCs are rather unique among cells of hematopoietic origin in that they undergo only 
part of their differentiation in the bone marrow, with the bulk differentiation occurring in peripheral 
tissues under the influence of the local microenvironment (Okayama & Kawakami, 2006). 
 
The bone marrow origin of MCs was first demonstrated through a series of in vivo reconstitution 
studies using genetically MC-deficient mutant mice (Kitamura et al., 1978; Kitamura et al., 1981). 
The WBB6F1-W/W
V
 mouse is MC-deficient due to a homozygous mutation at the white spotting 
locus (W); however, these mice are capable of developing MCs from homografts of bone marrow of 
their normal littermates. In contrast, WCB6F1-S1/S1
d
 mice that are MC-deficient due to 
homozygous mutation at the steel locus (S1) do not develop MCs under any circumstances 
(Kitamura & Go, 1979). However, the S1/S1
d
 mouse bone marrow cells develop into MCs after 
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intravenous injection into W/W
v
 mice (Kitamura & Go, 1979). These and other results suggested 
that W/W
v
 mice have abnormal bone marrow progenitors for MC, whereas Sl/Sl
d
 mice have normal 
bone marrow progenitors, but the microenvironment that induces MC differentiation is defective. 
The molecular explanations for these MC-deficiencies were provided when the W and S1 genes 
were cloned. The W locus contains c-kit proto-oncogene, which encodes the KIT receptor tyrosine 
kinase expressed on MCs and their progenitors, whereas the S1 locus encodes a hematopoietic 
growth factor called stem cell factor (SCF), steel factor, or kit ligand (KITLG) (Chabot et al., 1988; 
Geissler et al., 1988; Anderson et al., 1990; Flanagan & Leder, 1990), which is highly expressed on 
the surface of fibroblasts and stromal cells and also expressed in a non-membrane-bound secretable 
form (Witte, 1990). 
 
 
2.4.1. Bone marrow phase and mast cell progenitors 
 
In humans, pluripotent hematopoietic stem cells in the bone marrow first differentiate into common 
CD34
+ 
myeloid progenitor cells (Kirshenbaum et al., 1991). MCs can be derived from this 
population of CD34
+
 progenitor cells in the presence of KITLG, so defining human MC progenitors 
as CD34
+
/KIT
+
 cells (Kirshenbaum et al., 1999). Since also monocytes and granulocytes can be 
cultured from CD34
+
/KIT
+
 progenitors, several hypotheses about the relationship between MCs and 
other hematopoietic cells have been raised (Burnet, 1977; Zucker-Franklin, 1980; Czarnetzki et al., 
1982) However, in 1999, Kirshenbaum and colleagues noted that when the membrane-associated 
aminopeptidase N (CD13) was expressed on the CD34
+
/KIT
+
 cells, it served as a marker for a 
progenitor population that included MC and monocyte precursors, and thus distinguished this 
population of progenitors from granulocyte-committed precursors (Kirshenbaum et al., 1999). 
Moreover, lack of the monocyte-associated lipopolysaccharide receptor subunit (CD14) was earlier 
shown to distinguish MC progenitors from the population of progenitors that give rise to monocytes 
(Agis et al., 1993). In conclusion, circulating MC progenitors can be defined as 
CD34
+
/KIT
+
/CD13
+
/CD14
-
 to distinguish them from the CD34
+
/KIT
+
/CD13
+
/CD14
+
 and the 
CD34
+
/KIT
+
/CD13
-
 progenitors that give rise to monocytes and granulocytes, respectively (Agis et 
al., 1993; Kirshenbaum et al., 1999). Observations of other groups that have characterized human 
MC progenitors support the conclusion that human MCs derive from bone marrow progenitors as a 
default lineage, not functionally related to any other lineage (Rottem et al., 1994; Kempuraj et al., 
1999). 
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2.4.2. Peripheral differentiation phase 
 
From the circulating blood, the MC progenitors are recruited into various peripheral tissues. The 
processes of homing and migration of MCs to peripheral tissues have been extensively studied in 
mice. It has become apparent that MC homing in mice is a precisely controlled process, where 
integrin adhesion molecules play an important role (Hallgren & Gurish, 2011). Human MC 
progenitors have been reported to use α4β1-integrin for adhesive interactions with human vascular 
endothelium (Boyce et al., 2002). Furthermore, human MC progenitors express several chemokine 
receptors, CXCR2, CCR3, CXCR4, and CCR5, and respond to their ligands IL-8, eotaxin, stromal 
cell-derived factor (SDF)-1α, and macrophage inflammatory protein (MIP)-1α, respectively in vitro 
(Ochi et al., 1999).  
 
 
 
Figure 3. Two models for human MC development. MCs derive from pluripotent hematopoietic 
CD34
+
 stem cells in the bone marrow, leave the bone marrow as committed CD34
+
/KIT
+
 progenitor 
cells, and migrate through the bloodstream into peripheral tissues to undergo terminal 
differentiation under the influence of local growth factors and cytokines, most importantly KITLG. 
Two models for the development of MCT and MCTC have been suggested. First, MCT and MCTC 
derive from two distinct progenitors with irreversibly predetermined protease phenotypes, and no 
transdifferentiation between the two MC subtypes exists (Left panel). Second, MCT and MCTC 
derive from a common progenitor cell, and microenvironmental factors, such as cytokine milieu, 
ultimately determine the protease phenotype. Thus, MCT and MCTC can switch phenotypes along 
with changes in the local microenvironment (“Phenotypic plasticity”) (Right panel). Adapted from 
(Nigrovic & Lee, 2013). 
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The details of human MC differentiation in local tissue microenvironments are not well understood, 
and the developmental relationship between MCTC and MCT is particularly controversial: Are MCTC 
and MCT committed subsets deriving from two distinct progenitors with irreversibly predetermined 
protease phenotypes, or do they derive from a common progenitor cell and represent functional 
states that MCs assume under the influence of the local microenvironment (Fig. 3)? 
 
It has become obvious however that KITLG is the most important differentiation signal to MCs 
from the local microenvironment. KITLG elicits its functions, such as promotion of cell–cell and 
cell–substratum adhesion, proliferation, differentiation, maturation, and survival of MCs (Okayama 
& Kawakami, 2006),
 
through KIT, which is expressed widely on hematopoietic lineages early in 
differentiation, however, among mature lineages, only MCs express it at high levels (Ribatti & 
Crivellato, 2014). Stimulation of MCs by KITLG also blocks apoptosis, induces chemotaxis, and 
may activate MCs directly to release mediators. It is clear that the presence of KITLG is an absolute 
requirement for MC development and viability both in vivo and in vitro. Thus, mice with defects in 
KITLG (Sl/Sl
d
 mutants) or KIT (W/W
v
 mutants) are strikingly deficient in mature tissue MCs. On 
the other hand, clonal MCs obtained from patients with systemic mastocytosis characterized by 
uncontrolled MC proliferation commonly have autoactivating mutations of KIT (Carter et al., 
2014).  
 
Several factors are capable of regulating the KITLG-dependent MC development in both humans 
and mice. For instance, T lymphocytes have a profound impact on the phenotype and survival of 
local tissue MCs; intestinal biopsy specimens of human patients suffering from reduced T cell 
numbers due to congenital immunodeficiency or acquired immunodeficiency syndromes (AIDS) 
have shown that a reduction in T cell numbers is associated with strikingly reduced numbers of 
MCT, whereas MCTC are present in normal numbers (Irani et al., 1987; Bentley et al., 1996). 
Similarly, large numbers of MCT are identified in the inflamed synovium of patients with 
rheumatoid arthritis, typically in the regions rich in infiltrating leukocytes, whereas in normal 
synovium, MCTC is the predominating type observed (Gotis-Graham et al., 1997; Gotis-Graham et 
al., 1998). In  human cell culture systems, T cell-derived cytokines, such as interleukin (IL)-3, IL-4, 
IL-6, and IL-9, promote proliferation and maturation of MCs (Kirshenbaum et al., 1992; Kinoshita 
et al., 1999; Matsuzawa et al., 2003; Lappalainen et al., 2007) and may skew the MC phenotype 
toward either the MCT or MCTC (Toru et al., 1998; Kinoshita et al., 1999). Table 4 lists factors that 
are known to regulate MC development, proliferation, and survival. 
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Table 4. Growth factors and cytokines that regulate MC development, proliferation, and 
survival 
Growth Factor/ 
Cytokine 
Function 
KITLG ▪ Promotes proliferation, differentiation, survival, and cell–cell and cell–
substratum adhesion (Okayama & Kawakami, 2006) 
▪ Stimulates selective growth of MCs from hematopoietic progenitors (Irani et 
al., 1992; Valent et al., 1992; Kinoshita et al., 1999; Maaninka et al., 2013) 
▪ Induces expression of various MC neutral proteases (Maaninka et al., 2013)  
▪ Induces chemotaxis (Nilsson et al., 1994)  
▪ Activates mediator release (Columbo et al., 1992; Sperr et al., 1993)  
 
IL-3 ▪ Promotes development of MCs synergistically with KITLG (Kirshenbaum et 
al., 1992)  
▪ Promotes growth of mature MCs (Gebhardt et al., 2002)  
▪ Does not affect the differentiation of human MCs (Shimizu et al., 2008) 
 
IL-4 ▪ Promotes MC maturation accompanied with increased frequency of MCTC 
phenotype (Toru et al., 1998; Ahn et al., 2000)   
▪ Upregulates FcεRI expression (Toru et al., 1996; Xia et al., 1997; Iida et al., 
2001)  
▪ Increases mediator release (Iida et al., 2001)  
▪ Inhibits MC growth during early stage of development (Nilsson et al., 1994)  
▪ Induces apoptosis of MC progenitors (Oskeritzian et al., 1999) 
▪ Inhibits early KIT expression (Nilsson et al., 1994; Kulka & Metcalfe, 2005)   
 
IL-6 ▪ Promotes MC maturation accompanied with increased frequency of MCTC 
phenotype (Kinoshita et al., 1999; Moon et al., 2003)  
▪ Increases histamine content (Kinoshita et al., 1999) 
▪ Reduces/inhibits apoptosis (Kambe et al., 2001)  
 
IL-9 ▪ Increases proliferation of MC progenitors synergistically with KITLG during 
early stage of MC development (Matsuzawa et al., 2003; Lappalainen et al., 
2007) 
▪ Does not affect human MC differentiation (Lappalainen et al., 2007) 
▪ In mouse BMMCs, induce the expression of 'late-expressed' proteases 
mMCP-1 and mMCP-2 (Eklund et al., 1993) 
 
IFN-γ ▪ Inhibits MC growth and differentiation (Kirshenbaum et al., 1998) 
▪ Inhibits early progenitor cell division (Kulka & Metcalfe, 2005)  
▪ Promotes survival of cultured human MCs (Yanagida et al., 1996) 
 
NGF ▪ Promotes MC development (Welker et al., 2000)  
 
TGF-β ▪ Inhibits MC development (Kinoshita et al., 1999; Hjertson et al., 2003; Ishida 
et al., 2003) 
IFN-γ: interferon-γ; NGF: nerve growth factor; TGF-β: transforming growth factor-β 
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2.5. Tools to study mast cell protease expression 
 
Human cell culture systems are powerful tools to study protease expression in MCs. To utilize 
human MCs for studies three approaches are available: 1) to obtain human MC lines, HMC-1, 
LAD2, or LUVA (Butterfield et al., 1988; Kirshenbaum et al., 2003; Laidlaw et al., 2011); 2) to 
isolate MCs from human tissues, such as the lungs, intestinal mucosa, and skin (Kulka & Metcalfe, 
2010; Lorentz et al., 2015); and 3) to differentiate MCs in vitro from their progenitor cells present  
in human cord blood, peripheral blood of adult subjects, or bone marrow (Andersen et al., 2008). 
Regarding option 1, the MC lines represent MCs of relatively immature differentiation stages that 
express proteases only at low levels (Guhl et al., 2010). Regarding option 2, only a limited number 
of MCs can be isolated from tissues, and tissue MCs represent terminally differentiated cells, which 
do not usually divide in culture. Instead, in vitro differentiation of MCs from their progenitors 
ultimately yields high numbers of MCs, and thus option 3 is a method of choice when 
characteristics closely linked to MC development, such as protease expression, are to be 
investigated. 
 
Indeed, many groups have described sophisticated protocols for the in vitro generation of human 
MCs from their progenitors. However, virtually all studies that have used such protocols to study 
protease expression during MC differentiation have focused solely on tryptase and/or chymase 
expression, whereas no studies of CPA3, cathepsin G, and granzyme B expression during MC 
development had been reported at the time when the present experimentation was planned. The 
narrow focus has its roots in the long-held concept of the existence of two and only two human MC 
subtypes (MCT and MCTC), which are distinguished based on the absence or presence of chymase, 
respectively. However, studies that describe the presence within human tissues of MCs containing 
only chymase (MCC) (Weidner & Austen, 1993) and MCs containing tryptase and CPA3 (Abonia et 
al., 2010; Dougherty et al., 2010) provide strong evidence that human MC heterogeneity is more 
complex than initially suggested. To better understand the complexity of the phenotypic 
heterogeneity of human MCs, and to what extent such heterogeneity is intrinsically variable, it was 
important to challenge the tryptase/chymase dichotomy and to begin to appreciate the whole variety 
of human MC neutral proteases. 
 
 24 
 
3. AIM OF THE RESEARCH 
 
The objective of this Master's Thesis was to investigate expression pattern of various human MC 
neutral proteases, namely tryptase, chymase, CPA3, cathepsin G, and granzyme B during human 
MC development from their progenitors into mature MCs. Of particular interest was to investigate, 
whether human MC progenitor cells present in circulating blood differentiate in culture into 
different MC subtypes exhibiting heterogeneous protease phenotypes, or whether the expression of 
the various proteases is an intrinsic feature of all human MCs. 
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4. MATERIALS AND METHODS 
 
4.1. Purification of CD34
+
 progenitor cells from peripheral blood 
 
For in vitro experiments, MC progenitors were isolated from fresh buffy coats (concentrated 
leukocyte suspension) prepared from peripheral blood of voluntary donors, and supplied by the 
Finnish Red Cross Blood Transfusion Service (Helsinki, Finland) with the acceptance of the Ethics 
Committee of the Finnish Red Cross. A total of 40 ml of buffy coat suspension was first diluted 
two-fold in Ca
2+
- and Mg
2+
 -free Dulbecco's phosphate-buffered saline (PBS) (Biowhittaker, Lonza, 
Basel, Switzerland), and then separated by density gradient centrifugation over Ficoll-Paque PLUS 
(GE Healthcare, Uppsala, Sweden) into distinct phases that contained either erythrocytes, 
granulocytes, mononuclear cells, or plasma. For this purpose, 35 ml of the diluted blood sample was 
gently layered over 15 ml of Ficoll-Paque PLUS followed by centrifugation at 800 × g and 4°C for 
30 min (without braking). The interface layer of the peripheral blood mononuclear cells (PBMCs) 
was then harvested and washed three times with PBS by centrifuging the cell suspension first at 800 
x g and 4°C for 5 min, and then twice at 250 × g and room temperature for 5 min. Finally, the 
PBMCs were suspended in 50 ml of pre-chilled MACS buffer, which consisted of PBS 
supplemented with 0.5% bovine serum albumin (BSA) (Sigma-Aldrich, St Louis, MO, USA) and 2 
mM ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich), and the total number of PBMCs was 
determined using Coulter Counter T-540 (Beckman Coulter, Fullerton, CA, USA). After 
determination of the total cell yield, the PBMCs were sedimented by centrifuging them at 300 × g 
and room temperature for 10 min, and were subsequently used for CD34
+
 cell separation. 
 
CD34
+
 progenitor cells were enriched using positive immunomagnetic selection, a method that 
includes CD34
+
 cell separation kit and a magnetic LS
+
 separation column, according to the 
manufacturer's instructions (Miltenyi Biotec, Auburn, CA, USA). For this purpose, PBMCs were 
resuspended in pre-chilled MACS buffer at a concentration of 300 µl per 1 × 10
8
 cells. The Fc-
receptors were then blocked with human IgG followed by labeling of the cell surface antigens with 
CD34 hapten antibody (100 µl per 1 × 10
8
 cells) at 4 ºC for 15 min. After incubation, the cells were 
washed with pre-chilled MACS buffer by centrifuging them at 300 × g and room temperature for 6 
min, resuspended in MACS buffer at a concentration of 400 µl per 1 × 10
8
 cells, and incubated with 
CD34 anti-hapten MicroBeads (100 µl per 1 × 10
8
 cells) at 4ºC for 15 min. After washing with 
MACS buffer at 300 × g and room temperature for 6 min, the cells were resuspended in MACS 
buffer at a concentration of 500 µl per 1 × 10
8
 cells, and finally passed through the MACS 
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separation column placed in the magnetic field of the MACS separator. The magnetically labeled 
CD34
+
 cells were retained in the column, while the other cell types were eluted and discarded by 
washing the column four times with 4 ml of pre-chilled MACS buffer. After the washes, the column 
was removed from the magnetic field, and the CD34
+
 cells were eluted as the positively selected 
cell fraction with 5 ml of pre-chilled MACS buffer and washed once by centrifuging them at 300 × 
g and room temperature for 6 min. Finally, the CD34
+
 cells were resuspended in 2 ml of culture 
medium (described below), stained with 0.4% Trypan blue, and counted for evaluation of the cell 
yield. 
 
 
4.2. Cell culture 
 
The isolated CD34
+
 progenitor cells were grown on 12-well culture plates (Falcon, BD Biosciences, 
San José, CA, USA) under serum-free conditions according to a recently published protocol 
(Lappalainen et al., 2007). The basal culture medium consisted of Iscove's Modified Dulbecco's 
Medium (IMDM) with L-Glutamine and 25 mM Hepes (Biowhittaker, Lonza) supplemented with 
100 U/ml penicillin (Biowhittaker, Lonza), 100 μg/ml streptomycin (Biowhittaker, Lonza), 100 µM 
-mercaptoethanol (Sigma-Aldrich), 100 ng/ml recombinant human (rh)KITLG (PeproTech, Rocky 
Hill, NJ, USA), and 20% serum substitute, BIT 9500 supplement (containing BSA, human 
recombinant insulin and human transferrin) (Stem Cell Technologies, Vancouver, British Columbia, 
Canada). The basal culture medium was supplemented sequentially with rhIL-3 (5 ng/ml), rhIL-9 
(15 ng/ml), rhIL-6 (50 ng/ml) (PeproTech, Rocky Hill, NJ, USA) as well as human low-density 
lipoprotein (LDL) (10 g/protein/ml) that was prepared from the plasma of healthy volunteers 
supplied by Finnish Red Cross as described previously (Lappalainen et al., 2011). Medium changes 
were performed twice a week during the first three weeks of culture, and weekly thereafter. For that 
purpose, culture medium was first spun at 300 × g and room temperature for 6 min to sediment the 
cells, was then gently aspirated and replaced by fresh medium, after which the cells were 
transferred to grow on new culturing plates. During the culture period the concentration of the cells 
were kept around 0.5 × 10
6
 cells/ml. For the first four weeks, the cells were cultured at 37C in a 
humidified incubator flushed with a mixture of 5% O2, 5% CO2, and 90% N2 and thereafter under 
normoxic conditions (21% O2 and 5% CO2) at 37C. Cell viability was determined weekly by 
Trypan blue exclusion test. The cells were cultured for a total of 9 weeks, after which all cells were 
shown to express mature MC phenotype (Lappalainen et al., 2007).  
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4.3. Flow cytometry 
 
Expression of tryptase, chymase, cathepsin G, granzyme B, and CPA3, as well as histidine 
decarboxylase (HDC) as an indicator for cellular histamine, was followed on weekly basis during 
the MC development by flow cytometry using a fluorescence-activated cell sorter (FACS) LSR II 
(BD Biosciences). Double staining with KIT (or c-KIT) was used to distinguish MCs from other 
cell types, for example from macrophage/monocytes and basophils. The antibodies and their 
concentrations are listed on Table 5. 
 
For flow cytometry, 2 x 10
5
 cells per sample were collected and sedimented by centrifuging them at 
300 x g and room temperature for 6 min. The cells were then resuspended in pre-chilled FACS 
buffer (sterile-filtered through 0.2 m pore size membrane, Corning, NY, USA) consisting of 0.5% 
BSA (Sigma-Aldrich) and 0.025% sodium azide (Sigma-Aldrich) in PBS, and then centrifuged at 
300 × g and 4ºC for 6 min. Next, the cells were resuspended in FACS buffer at a concentration of 2 
× 10
5
 cells/50 µl and transferred to a 96-well Sarstedt plate (Sarstedt Microtest 96-well Plates with 
V-shape bottom). The cells were fixed by adding 50 µl of 4% paraformaldehyde (PFA, Sigma-
Aldrich) in PBS and by incubating for 15 min at room temperature, after which the cells were 
washed once with 150 µl of FACS buffer at 300 × g and room temperature for 5 min, and 
resuspended in a 50 µl of FACS buffer. For double-staining of the cell surface antigens FcεRI and 
KIT, the cells were first incubated with phycoerythrin (PE)-conjugated mouse anti-human FcεRI, or 
its negative control for 30 min at 4C, after which the excess antibody was washed by centrifuging 
the cells with 250 μl of FACS buffer at 300 × g and room temperature for 5 min. The cells were 
then resuspended in 50 μl of FACS buffer and incubated with allophycocyanin (APC)-conjugated 
mouse anti-human CD117 (KIT), or its negative control for 30 min at 4C. The excess antibody was 
again washed by centrifuging the cells with 250 μl of FACS buffer at 300 × g and room temperature 
for 5 min, and finally, the cells were resuspended in 250 μl of FACS buffer. 
 
For double-staining of the proteases/HDC and KIT, the fixed cells were permeabilized in 100 μl of 
0.5% Saponin (Sigma-Aldrich) in FACS buffer by incubating them for 20 min at room temperature. 
Next, primary antibodies against tryptase, chymase, cathepsin G, CPA3, granzyme B, and HDC, or 
their negative controls, were added and incubated with the cells for 60 min at 4C. Excess 
antibodies were washed by centrifuging the cells twice with 200 μl of 0.25% saponin in FACS 
buffer at 300 x g and room temperature for 5 min. Next, the cells were resuspended in 50 μl of 
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0.25% saponin in FACS buffer and secondary antibodies were added and incubated with the cells 
for 40 min at 4C. Excess antibodies were washed by centrifuging the cells twice with 200 μl of 
0.25% Saponin in FACS buffer at 300 x g and room temperature for 5 min. The cells were 
resuspended in 80 l of FACS buffer and stained against KIT by incubating them with APC-
conjugated mouse anti-human CD117, or its negative control for 30 min at 4C. Finally, the cells 
were washed by centrifuging them twice with 200 μl of FACS buffer at 300 × g and room 
temperature for 5 min. Just before analysis, the cells were transferred to 5 ml FACS tubes (Falcon, 
Becton Dickinson, Franklin Lakes, NJ, USA) and 250 μl of pre-chilled FACS buffer was added to 
each sample. The FACS analysis was performed with 1.0 × 10
4
 cells per sample by FlowJo software 
from TreeStar Inc. (Ashland, OR, USA). To eliminate any contaminating cells from being analyzed, 
KIT
+ 
cells were first gated followed by examination of FcεRI or intracellular proteases/HDC (Fig. 
4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. A representative plot of flow cytometric analysis of the human peripheral blood CD34
+ 
progenitor-derived mast cells at 6 weeks of culture. Quadrant plots were created to evaluate the proportion 
of cells double-positive for KIT and the investigated proteases/HDC/FcεRI. Viable cells were determined 
according to straight and forward scatters (SSC and FSC) (A). Fluorescence thresholds for positive staining 
were set by irrelevant isotype-matched immunoglobulins (B). Cells were then gated by their high surface 
expression of KIT (C), which excluded any contaminating cell types from being analyzed. Finally KIT
+
 cells 
were analyzed for FcεRI or intracellular proteases/HDC (D). 
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* Used only for immunofluorescence microscopy 
Table 5. Antibodies used for FACS and immunocytochemical stainings of mast cell proteases 
Antibody Isotype Clone Manufacturer Concentration Final concentration Label 
Primary antibodies       
CD117/KIT       
Mouse anti-hu CD117 mAb IgG1 YB5.B8 eBiosciences 0.025 mg/ml 5 μg/ml APC 
Mouse anti-hu CD117 mAb IgG1 YB5.B8 BD Pharmingen 0.2 mg/ml 4 μg/ml APC 
Isotype-matched negative control       
Mouse IgG isotype control IgG1 MOPC-21 BD Pharmingen Not available 1:5 APC 
IgERI       
Mouse anti-hu IgERI mAb  IgG1 CRA-1 BioSite Not available 1:10 PE 
Mouse anti-hu IgERI mAb  IgG1 AER-37 eBiosciences Not available 1:10 PE 
Isotype-matched negative control       
Mouse IgG negative control IgG1 203 ImmunoTools Not available 1:10 PE 
Mouse IgG negative control  IgG1 Not applicable AbD Serotec Not available 1:10 PE 
Granzyme B       
Mouse anti-hu Granzyme B mAb IgG1 GB11 ImmunoTools Not available 1:10 PE 
Mouse anti-hu Granzyme B mAb IgG1 GB11 AbD Serotec Not available 1:10 PE 
Rabbit anti-hu Granzyme B pAb* Not applicable Not applicable Abcam Not available 1:10  
Isotype-matched negative control       
Mouse IgG negative control  IgG1 203 ImmunoTools Not available 1:10  
Mouse IgG negative control IgG1 Not applicable AbD Serotec Not available 1:10 PE 
Tryptase       
Mouse anti-hu tryptase mAb IgG1 AA1 AbD Serotec 1 mg/ml 10 μg/ml  
Chymase       
Mouse anti-hu chymase mAb IgG1 B7 Chemicon/Millipore 1.6 mg/ml 3.2 μg/ml  
Isotype-matched negative control       
Mouse IgG negative control IgG1 Not applicable AbD Serotec Not available 1:30  
Cathepsin G       
Rabbit anti-hu cathepsin G pAb Not applicable Not applicable Abcam Not available 1:100  
Isotype-matched negative control       
Rabbit IgG negative control Not applicable Not applicable Jackson laboratories 1 mg/ml 0.4 μg/ml /1 μg/ml  
CPA3       
Rabbit anti-hu CPA3 pAb Not applicable Not applicable Sigma-Aldrich 0.11 mg/ml 0.22 μg/ml  
Rabbit anti-hu CPA3 pAb Not applicable Not applicable Sigma-Aldrich 0.01 mg/ml 0.4 μg/ml (2 μg/ml*)  
HDC       
Rabbit pAb to HDC Not applicable Not applicable Abcam 0.2 mg/ml 2 μg/ml  
IgG isotype control       
Rabbit IgG negative control Not applicable Not applicable Jackson laboratories 11 mg/ml 2.2 μg/ml (10 μg/ml*)  
Rabbit IgG negative control Not applicable Not applicable Jackson laboratories 1 mg/ml 0.4 μg/ml/ 1 μg/ml  
Secondary antibodies       
Donkey pAb to Rabbit IgG H&L  F(ab)2 fragment Not applicable Abcam 0.5 mg/ml 5 μg/ml PE 
Sheep anti-rabbit Full IgG Not applicable AbD Serotec NA 1:5 PE 
Goat anti-mouse IgG  Full IgG Not applicable BD Pharmingen 0.2 mg/ml 2 μg/ml PE 
Goat anti-mouse IgG  F(ab)2 fragment Not applicable Molecular Probes 2 mg/ml 4 μg/ml FITC 
Goat anti-rabbit IgG  Full IgG Not applicable Molecular Probes 2 mg/ml 4 μg/ml FITC 
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4.4. Quantitative real-time reverse-transcription PCR  
 
To evaluate the mRNA expression levels of tryptase, chymase, CPA3, cathepsin G, granzyme B as 
well as HDC, qRT-PCR was used. The protease and HDC expressions in developing MCs were 
followed on a weekly basis at compatible time points to flow cytometric analysis. 
 
 
4.4.1. Total RNA isolation 
 
Total RNA was isolated from developing MCs on a weekly basis, starting at week 1 of culture, with 
RNeasy mini kit according to the manufacturer's instructions (Qiagen Inc., Valencia, CA, USA). 
The developing MCs (0.5 × 10
6
 cells per culture) were harvested and lysed in 350 μl of RLT PLUS 
Buffer, supplemented with 1% -mercaptoethanol (Sigma-Aldrich). The formed cell lysate was 
homogenized by flicking the cell suspension back and forth 5 times through a 19-gauge needle. To 
precipitate the RNA present in the cell lysates, 350 μl of 70% ethanol was added to the lysates and 
mixed carefully. Next, the solution was transferred into a RNA spin column in a 2 ml collection 
tube and centrifuged at 10 000 × rpm for 15 s [all centrifugation steps were performed at room 
temperature with Centrifuge 5424 (Eppendorf AG, Hamburg, Germany)]. The spin column was 
washed by centrifuging with 350 μl of the RW1 buffer at 10 000 × rpm for 15 s. The flow-through 
was discarded, and 80 μl of 1:8 RNase-free DNase I in RDD buffer was added to RNA spin column 
membrane to eliminate any remnants of genomic DNA. After 15-min incubation at room 
temperature, 350 μl of the RW1 buffer was added to the RNA spin column and the column was 
centrifuged at 10 000 × rpm for 15 s. The flow-through volume was discarded, and 500 μl of RPE 
buffer was added to the spin column twice, so that the column was first centrifuged at 10 000 x rpm 
for 15 s and then at 10 000 × rpm for 2 min. The flow-through volume was again discarded, and the 
spin column was transferred to another 2 ml collection tube and centrifuged at 10 000 × rpm for 1 
min to dry the spin column membrane. Finally, RNA was eluted from the column with 30 μl of 
RNase-free water by centrifuging the column at 10 000 × rpm for 2 min in 1.5 ml collection tube. 
The RNA concentration was then measured with NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies, Thermo Scientific, Wilmington, DE, USA) in a sample volume of 1.5 μl. 
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4.4.2. Complementary DNA synthesis from total RNA 
 
For complementary DNA (cDNA) synthesis, 250 ng of total RNA per sample was reverse 
transcribed in a reaction mixture consisting of 0.01 μM dNTP mix (Promega Madison, WI, USA), 
200 ng random primers (Promega), 5X First-Stand Buffer (Promega), 20 U RNase Inhibitor 
(Promega), 100 U M-MLV RT (Promega), and RNase-free water in a final volume of 20 μl. First 
the RNA, dNTP mix, random primers, and RNase-free water was added to a 0.2 ml PCR tubes, 
incubated at 65˚C for 5 min, and immediately placed on ice. Next, 5X First-Strand Buffer, RNase 
Inhibitor, M-MLV RT enzyme, and RNase-free water were added to each sample tube and mixed 
gently, after which the samples were reverse transcribed as follows: primer annealing at 25˚C for 8 
min, followed by first strand synthesis at 48˚C for 55 min, and termination at 85˚C for 10 min. 
Finally, the samples were chilled at 4˚C, spun down by brief centrifugation at room temperature, 
diluted four-fold in PCR grade water, and used for qRT-PCR.  
 
 
4.4.3. qRT-PCR 
 
A TaqMan, or alternatively SYBR Green, analysis was performed using ABI PRISM 7500 
sequence detector (Applied Biosystems, Foster City, CA). Five microliters of the diluted cDNA 
from 250 ng of total RNA was amplified in duplicates using TaqMan Universal PCR Master Mix or 
Power SYBR Green Master Mix (both from Applied Biosystems) together with 400 nM primers 
and 200 nM FAM-labeled fluorogenic probes (SYBR Green assays were performed without a 
fluorogenic probe) in a final volume of 25 μl. The forward and reverse oligonucleotide primers as 
well as TaqMan probes (Table 6) were in-house designed and synthesized by Biomers (Ulm, 
Germany). The thermocycling conditions for the qRT-PCR assay consisted of an initial step of  
 
 
Table 6. Primers and probes used in quantitative real time-PCR 
Gene SS Primer AS Primer Probe 
Tryptase CGATGTGGACAATGATGAGC CGCCAAGGTGGTATTTTGC   
Chymase TGCTCATTGTGCAGGAAGGTC ACCTCAAGCTTCTGCCATGTG   
CPA3 CCAGATGCTATTGTTTCCCTATGG GTAGCGGGTTTCATATCGAGTTG FAM -CCATGAGGACTTGGCCAAAGTTGCA -BHQ-1 
Cathepsin G GGTTCCTGGTGCGAGAAGAC GATGTGTTGCTGGGTGTTTTC FAM–AAGCAATATAAATGTCACCCTGGGCGC-BHQ-1 
Granzyme B GGAAGATCGAAAGTGCGAATC CTGGGCCACCTTGTTACACA FAM-CCTCCAGAGTCCCCCTTAAAGGAAGTCT-BHQ-1 
HDC CTGATGCCATCCAACTGCTTG TTGCCAACCAGTCCATGAG FAM-TCACCTGGGCATCCAGCCCTG-BHQ-1 
18s CGGCTACCACATCCAAGGAA GCTGGAATTACCGCGGCT FAM-TGCTGGCACCAGACTTGCCCTC-BHQ-1 
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95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 15 s, and annealing and 
extension at 60°C for 1 min. PCR-grade water was included in each assay to replace the cDNA 
template as a no template control. For data normalization an endogenous control, 18S ribosomal 
(r)RNA was determined for controlling cDNA input and PCR amplification. 
 
The data was developed with Sequence Detector System software (version 1.4, Applied 
Biosystems), the threshold value (Ct) of a sample was selected according to the manufacturer's 
guidelines, and the relative units were calculated by a comparative Ct method. First, the difference 
between the Ct of the 18S rRNA and the corresponding target gene was calculated for 
Δ
Ct. For the 
calibrator 
Δ
Ct, the average Ct of 18S rRNA from each sample was subtracted from the calibrator Ct 
value of 40, which was obtained from the no template control (molecular-grade water). Next, the 
calibrator 
Δ
Ct was subtracted from the 
Δ
Ct of each experimental sample to obtain the 
ΔΔ
Ct. Finally, 
the amount of target normalized to an endogenous control was calculated by the equation 2
–ΔΔCt
 
(Livak & Schmittgen, 2001). 
 
 
4.5. Immunocytochemical stainings of mast cell proteases 
 
Identification of tryptase, chymase, CPA3, cathepsin G, and granzyme B in mature MCs was 
performed by immunocytochemical stainings. The antibodies used for immunocytochemical 
stainings are listed on Table 5. Ten thousand MCs per sample were centrifuged onto glass slides by 
Cytospin (Shandon, Thermo Scientific) at 600 x rpm and room temperature for 6 min. After 
allowing the slides to air-dry, the cells were fixed with methanol supplemented with 10% MeS 
Buffer that consisted of 100 mM MeS (2-morpholinoethanesufonic acid), 1 mM EGTA (ethylene 
glycol tetraacetic acid), and 1 mM MgCl2, at room temperature for 5 min. Next, the samples were 
washed three times with PBS for 5 min each, after which the non-specific binding sites of MCs 
were blocked with 80 μl of 3% goat serum in PBS for 30 min at room temperature. Next, the serum 
was replaced by 80 μl of the primary antibodies against tryptase, chymase, CPA3, cathepsin G, and 
granzyme B, or by 80 μl of their isotype-matched negative controls, and the slides were incubated 
for 120 min in a humidified chamber at 4ºC. Excess antibody was washed with 0.05% Tween 20 
(Sigma-Aldrich) in PBS for 5 min, and then two times 5 min with PBS only. Next, the secondary 
antibodies were added to the slides and incubated for 60 min in the humidified chamber at room 
temperature. Excess antibody was again washed with 0.05% Tween 20 in PBS and then two times 5 
min with PBS only, and the cell nuclei were quickly stained with 20 μg/ml of DAPI (4',6-
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diamidino-2-phenylindole, Sigma-Aldrich). Finally, the samples were washed once with distilled 
water, mounted with Fluorescent mounting media (Sigma-Aldrich) and cover slips, and inspected 
under Nikon Eclipse E600 fluorescence microscopy (Nikon Instruments Europe B.V., Amsterdam, 
Netherlands). The pictures were taken with Spot RT and by SpotAdvenced software both from 
Diagnostics Instruments (Sterling Heights, MI, USA). 
 
 
4.6. Cellular histamine 
 
The expression of cellular histamine was measured on a weekly basis using enzyme-linked 
immunosorbent assay (ELISA) according to the manufacturer's instructions (IBL, Boise, ID, USA). 
The cells, 0.15 × 10
6
 MCs per sample, were harvested, sedimented with their culture medium (at 
300 × g and room temperature for 5 min), and lysed in 50 μl of 0.5% Triton-X 100 (Sigma-Aldrich) 
in water. The cell lysates were then diluted in water, and 50 μl of each diluted sample and of each 
standard were transferred into 5 ml glass tubes. Next, 50 μl of Indicator Buffer and 10 μl of 
Acylation Reagent were added into each tube, and the samples were immediately mixed and 
incubated at room temperature for 30 min. After incubation, 2 ml of Assay Buffer (diluted five-fold 
in water) was added into each tube, which were then mixed thoroughly. Next, 50 l of each 
acylated standard and acylated sample were transferred into the respective wells of a microtiter 
plate, after which 50 μl of freshly prepared Enzyme Conjugate and 50 μl of Histamine Antiserum 
were added into each well. The samples were then incubated for 180 min on an orbital shaker at 
room temperature, and after incubation, washed 4 times with 250 μl of freshly prepared Wash 
Buffer. The excess solution was removed and 100 μl of 3,3′,5,5′-Tetramethylbenzidine (TMB) 
Substrate Solution was added to the samples and standards, and incubated on an orbital shaker at 
room temperature for 20 min. The reaction was stopped by adding 100 μl of TMB Stop Solution 
into each well, and the optical densities at 450 nm were measured immediately with a Wallac Victor 
3 (Perkin-Elmer, Turku, Finland). 
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5. RESULTS 
 
5.1. Cell culture 
 
CD34
+
 progenitor cells were derived from the peripheral blood of healthy volunteers and cultured 
under a recently developed protocol in the presence of rhKITLG and various cytokines to allow 
them to differentiate into mature MCTC type of MCs during 9 weeks of culture (Lappalainen et al., 
2007). The yield of PBMC from one buffy coat was, on average, 490 × 10
6
 cells (n=7 donors), of 
which, 0.3% on average were ultimately cells recovered as CD34
+
 after the positive 
immunomagnetic selection. The culture was initiated with approximately 1.5 × 10
6
 CD34
+
 cells. 
During the culture, variation in the dividing potential between MCs of different donors was 
observed, and accordingly, the time an individual donor contributed to the analyses ranged from 5 
to 9 weeks. 
 
 
5.2. Antigen expression by flow cytometry 
 
5.2.1. KIT and FcεRI 
 
Expressions of KIT and FcεRI were analyzed on a weekly basis during MC development to confirm 
the purity of the cultures. As shown in Fig 5 (left panel), a small number (<10%) of primitive 
CD34
+ 
progenitors
 
expressed KIT already at their isolation from the blood (at day 0). At week 1 of 
culture, the vast majority of the cells in culture stained positively for KIT, the proportion of KIT
+ 
cells ranging from 60% to 96% of all cells depending on the donor. By 2 weeks the proportion of 
KIT
+
 cells had a tendency to drop to a range of 45% to 93%. Nevertheless, two of the donors 
increasingly expressed KIT at this point. After 2 weeks, the KIT-positivity again started to increase, 
and by 3 weeks the proportion of the KIT
+
 cells started to equalize between different donors. At this 
point, 70% to 93% of the cultured cells stained positively for KIT. Beyond this time, the expression 
of KIT increased until up to 6 weeks, at which point more than 95% of the cells were positive for 
KIT among all donors. Besides the increase in proportion of KIT
+
 cells, the positivity in terms of 
mean fluorescence intensity (MFI) had a tendency to increase along with culture (data not shown). 
The analysis of FcεRI expression was initiated at 1 week of culture, and as shown (Fig 5; right 
panel), a fraction of the primitive MC progenitors was positive for this receptor already at that time. 
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Expression of FcεRI increased steadily up to 3 weeks, by which time more than 90% of the MCs 
were characterized as FcεRI+. At week 6, virtually all MCs were positive for FcεRI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Expressions of KIT and FcεRI on human peripheral blood CD34+ progenitor-
derived MCs during culture. The figure illustrates the percentage of KIT- (Left panel) and FcεRI- 
(Right panel) positive cells of all cells in the culture at various culture weeks. The data are means ± 
SD from at least four donors. SD; standard deviation. 
 
 
 
5.2.2. Mast cell proteases and histidine decarboxylase 
 
All proteases investigated herein were detected at the protein level by flow cytometry during the 
MC development. The flow cytometric analysis showed that each protease was expressed at 
detectable level in developing MC precursors as early as week 1 of culture. The amount of protease-
positive cells increased relatively steadily by 3 weeks, at which point virtually all MCs were 
positive for tryptase and chymase (Fig 6; left panel). A slight delay was observed in the expressions 
of cathepsin G, CPA3, and granzyme B, compared to tryptase and chymase, however, by week 6-7, 
virtually all MCs stained positively for all the investigated proteases. Furthermore, besides the 
increase in the proportion of the protease-positive cells, an increase in the protease-positivity (in 
terms of MFI) was also observed along with culture (data not shown). No distinct protease-positive 
and protease-negative populations were observed at any time point during the analysis, only a single 
continuous population of MCs expressing each investigated protease at variable levels. The 
expression of HDC followed a nearly identical pattern to those of CPA3, cathepsin G, and 
granzyme B (Fig. 6; left panel). 
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Figure 6. Protease and histidine decarboxylase expressions in human peripheral blood CD34
+ 
progenitor-derived mast cells by flow cytometry and qRT-PCR. The left panel illustrates the 
percentage of protease/HDC positive MCs of all MCs in the culture at various weeks. The right 
panel illustrates mRNA expression levels of the proteases/HDC at various weeks as fold increases 
compared to week 1. The data are means ± SD from at least four donors. SD; standard deviation. 
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5.3. mRNA analysis by qRT-PCR 
 
5.3.1. Tryptase 
 
Tryptase mRNA levels were detected already at 1 week of culture and the levels slightly increased 
during the second week of culture and subsequently appeared to significantly increase at 3 weeks of 
culture, by which time a relatively constant level of expression was reached. In terms of absolute 
values (data not shown), tryptase was expressed at the highest levels, and as shown in Fig 6 (right 
panel), reached a relatively steady state level of expression at an early stage of MC development, 
that is, at 3 weeks of culture.  
 
 
5.3.2. Chymase 
 
Chymase was also expressed at detectable level already at 1 week of culture, and the expression 
levels continued to increase during the second week. By 3 week, a similar tendency of remarkable 
increase in the mRNA expression levels that was noted with tryptase was also observed with 
chymase, however, the increase was significantly greater compared to that of tryptase (Fig 6; right 
panel). After 3 weeks, a relatively steady level of expression was observed without a decline in 
expression by 9 weeks. Of all the investigated proteases, expression levels of chymase varied the 
most between MCs of different donors.  
 
 
5.3.3. Carboxypeptidase A3 
 
The third main MC protease, CPA3, followed similar expression pattern as observed with tryptase 
and chymase as being detectable at 1 week, increasing on the third week, and reaching a steady 
level after 3 weeks of culture (Fig 6; right panel). In terms of absolute values, CPA3 was expressed 
at relatively similar levels among the different donors. Furthermore, CPA3 was expressed at levels 
comparable to chymase, with the exception of the first week, during which CPA3 expression 
dominated over chymase. 
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5.3.4. Cathepsin G 
 
The mRNA for cathepsin G was expressed at detectable level at 1 week of culture and increased 
remarkably by 3 weeks of culture (Fig 6; right panel). However, the mRNA expression of cathepsin 
G still increased after 3 weeks, peaking at week 6 of culture, and a relatively steady level was 
observed at a slightly more advanced stage of cell maturation when compared to tryptase, chymase, 
and CPA3. In terms of absolute values, MCs expressed cathepsin G at a slightly lower level than 
chymase and CPA3.  
 
 
5.3.5 Granzyme B 
 
The expresion of granzyme B appeared to differ from the relatively uniform expression patterns of 
the neutral proteases described above (Fig 6; right panel). However, mRNAs for granzyme B were 
also detected already at first week of the culture and increased during the second week of culture. 
However, no increase in the levels of granzyme B mRNA was observed on the third week as was 
noted with tryptase, chymase, CPA3, and cathepsin G. Instead, the mRNA expression had a 
tendency to decrease during the third week of culture. A remarkable peak at the mRNA levels was 
observed at 6 weeks of culture. To exclude any technical problems in the assay, granzyme B mRNA 
analysis was performed twice and identical results were obtained. In terms of absolute values, 
granzyme B was expressed at very low levels compared to the other neutral proteases: for example, 
the expression of tryptase was, on average, 3 × 10
6
-fold compared to that of granzyme B (data not 
shown). 
 
 
5.3.6. Histidine decarboxylase 
 
The mRNAs for HDC were also detected at the first culture week and remained near this level also 
during the second culture week (Fig 6; right panel). After 3 weeks of culture an increase in the 
expression levels was observed, and beyond that time a relatively constant level of expression was 
achieved without decline in the expression by 9 weeks of culture when the analysis was 
discontinued. Compared to the neutral proteases, HDC was expressed at relatively constant levels 
between MCs of different donors. 
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5.4. Cellular histamine  
 
Histamine measurement was initiated at 3 weeks of culture. At that time the amount of cellular 
histamine was, on average, 1 pg/cell (n=2 donors in duplicate experiments). The amount of 
histamine remained at this level up to 4 weeks of culture, and beyond that time increased along with 
culture being on average 8.5 pg/cell (n=2 donors in duplicate experiments) at the time of 9 weeks 
when the culture was discontinued (Fig 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Histamine content in developing MCs. Data are means ± SD from at least two donors in 
duplicate experiments. SD; standard deviation. 
 
 
5.5. Immunocytochemical stainings of mature mast cells 
 
To compare the sensitivity of fluorescence microscopy to flow cytometry in detecting neutral 
protease expression, cytospins of cultured MCs at week 9 of culture were perfomed and stained 
with antibodies against human tryptase, chymase, cathepsin G, CPA3, and granzyme B. As shown 
in Figure 8, there was negligible autofluorescence or nonspecific binding in the samples based on 
isotype controls. Tryptase and cathepsin G stained the most intensively followed by chymase and 
CPA3. In contrast, granzyme B stained only weakly. Most importantly, some of the MCs appeared 
almost devoid of a particular protease (chymase and CPA3), even when flow cytometry clearly 
showed that all MCs were positive for all studies proteases at this time point. This observation 
addresses the critical dependence of the result on the detection method. 
p
g
/c
el
l 
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Figure 8. Immunocytochemical stainings of human peripheral blood CD34
+
 progenitor-
derived mast cells at 9 weeks of culture. Cells stained positively with mouse monoclonal 
antibodies against chymase and tryptase, and with rabbit polyclonal antibodies against cathepsin G, 
carboxypeptidase A3, and granzyme B. A fluorochrome-conjugated goat anti-mouse Alexa-488 IgG 
(for chymase and tryptase) or goat anti-rabbit Alexa-488 IgG (for cathepsin G, carboxypeptidase 
A3, and granzyme B) was used as the secondary antibody. Nuclei were stained with DAPI. 
Stainings with irrelevant IgGs (mouse IgG for tryptase and chymase, and rabbit IgG for cathepsin 
G, carboxypeptidase A3, and granzyme B) were used as negative controls. 
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6. DISCUSSION 
 
The present thesis is partly based  on a previously published study, which described a novel human 
MC phenotype, namely the tryptase
+
, chymase
+
, CPA3
+
, cathepsin G
+
, and granzyme B
+
 MC 
(Maaninka et al., 2013). Before that study, four MC protease phenotypes had been reported within 
human tissues: 1) tryptase
+
, chymase
-
 MC (MCT); 2) tryptase
+
, chymase
+
, CPA3
+
, cathepsin G
+
 MC 
(MCTC); 3) chymase
+
, tryptase
-
 MC (MCC); and 4) tryptase
+
, CPA3
+ 
(Irani et al., 1986; Schechter et 
al., 1990; Irani et al., 1991; Weidner & Austen, 1993; Abonia et al., 2010; Dougherty et al., 2010). 
In human culture systems, the development of tryptase
+
, chymase
-
 MC (MCT), tryptase
+
, chymase
+
 
MC (MCTC), and chymase
+
, tryptase
-
 MC (MCC) had been demonstrated (Irani et al., 1992; Li et al., 
1996; Toru et al., 1998; Kinoshita et al., 1999; Ahn et al., 2000; Shimizu et al., 2002; Lappalainen 
et al., 2007). Saito and coworkers had described cultured human MCs, which express transcripts for 
β-tryptase, chymase, CPA3, and cathepsin G (Saito et al., 2001), and granzyme B had been 
identified in cultured human MCs and in MCs isolated from human skin (Strik et al., 2007). 
Furthermore, after publication of the study, which this thesis is based on (Maaninka et al., 2013), 
yet another neutral protease, namely granzyme H have been identified within human MCs 
(Rönnberg et al., 2014). 
 
Several protocols for in vitro differentiation of human MCs from their progenitors have been 
described (Irani et al., 1992; Kirshenbaum et al., 1992; Mitsui et al., 1993; Saito et al., 1996; Xia et 
al., 1997; Toru et al., 1998; Kinoshita et al., 1999; Ahn et al., 2000; Kambe et al., 2000; Kambe et 
al., 2001; Shimizu et al., 2002; Moon et al., 2003; Wang et al., 2006; Lappalainen et al., 2007). In 
such studies, MCs have been differentiated from their progenitors present in the bone marrow, fetal 
liver, cord blood, and peripheral blood under KITLG alone or in combination with T helper 2 (Th2) 
cytokines, such as IL-3, IL-4, IL-6, and IL-9. Differentiation under such conditions has yielded 
cultures comprising variable amounts of MCTC and MCT subtypes, and cultures consisting of MCs 
of the MCTC subtype exclusively. Irani and coworkers described the development of MCs from 
dispersed human fetal liver cells cultured with murine Swiss 3T3 fibroblasts (Irani et al., 1992). In 
these cultures MCT was the primary subtype observed. By day 30, there was no evidence of 
conversion of the MCT type into the MCTC type. Accordingly, the authors concluded that MCT and 
MCTC derive from two distinct progenitors with irreversibly predetermined protease phenotypes. 
Similarly, ultrastructural analysis of maturing human MCs in situ has led to conclusion that MCT 
and MCTC are committed subtypes (Craig et al., 1989).  
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The development in vitro of mainly MCT subtype in the presence of KITLG solely initially led to 
conclusion that KITLG alone might be insufficient to promote development of MCTC (Irani et al., 
1992; Mitsui et al., 1993). However, Ahn and coworkers have demonstrated that human cord blood-
derived MC progenitors develop into MCTC exclusively even when cultured under KITLG alone, an 
observation suggesting that all human MCs are capable of expressing chymase (Ahn et al., 2000). 
Ahn and coworkers also reported that chymase expression in cultured human MCs is clonally 
regulated at the progenitor level. Such cytokine-independent regulation of chymase expression 
could lead to apparent variation in chymase expression levels between MCs even in a single culture 
of MCTC. The potential clonal regulation of other studied proteases is unclear; yet, MCs appear to 
express each neutral protease at a variable level, as indicated by the differences in fluorescence 
intensities observed in the present study by both flow cytometry and fluorescence microscopy. 
Indeed, light microscopy, including fluorescence microscopy, and flow cytometry have been widely 
used to detect MC neutral proteases stained with specific antibodies. Of these, flow cytometry is far 
more sensitive in detecting proteins, and was therefore used to detect MC neutral granule proteases 
in the present study. However, as a comparison, protease expression was also analyzed by 
immunofluorescence microscopy. As judged by the latter method, some of the MCs appeared 
devoid of chymase and CPA3, even when flow cytometry clearly showed that all MCs were 
positive for both neutral proteases. Such observation implies that the apparent protease-positivity of 
a MC may critically depend on the sensitivity of the detection method, which again may lead to 
variation in relative numbers of a particular MC subtype reported in any given sample based on the 
method used.  
 
By reporting the development of a single tryptase
+
, chymase
+
, CPA3
+
, cathepsin G
+
, granzyme B
+ 
population of human MCs from their progenitors present in peripheral blood, the present Thesis 
suggests that all human MCs are capable of expressing a full set of the investigated neutral 
proteases. Given that KITLG alone is sufficient to induce tryptase and chymase expression in 
human MCs, it is intriguing to speculate KITLG as a common inducer of MC neutral protease 
expression in general. Indeed, this was confirmed by analyzing the expressions of tryptase, 
chymase, CPA3, cathepsin G, and granzyme B in MCs generated in the presence of KITLG alone 
(Maaninka et al., 2013). Binding of KITLG to KIT recruits downstream signaling molecules, 
including lineage-restricted factors, such as the basic helix-loop-helix leucine zipper transcription 
factor called microphthalmia transcription factor (MITF) (Phung et al., 2011). In humans, MITF-A 
is the major MITF isoform in MCs, and it regulates the transcription of βI-tryptase (Lee et al., 
2010). However, in mice, MITF regulates the expression of several MC chymase and tryptase 
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genes, as well as the genes coding for cathepsin G and granzyme B (Pejler et al., 2007). Thus, 
MITF might be a key target of KITLG in the regulation of MC proteases in general. The recent 
study of Rönnberg and coworkers (Rönnberg et al., 2013) demonstrates that expression of 
granzyme D, the functional counterpart of human granzyme H, accompanies the KITLG-dependent 
differentiation of bone marrow precursors into mature bone marrow-derived MCs, supporting the 
hypothesis of KITLG as a common inducer of MC neutral proteases.  
 
The data of the present Master’s Thesis and the study, which this Thesis is based on (Maaninka et 
al., 2013) suggest that the expressions of tryptase, chymase, CPA3, cathepsin G, and granzyme B 
are an intrinsic feature of human MCs, and no distinct MC progenitors with irreversibly 
predetermined protease phenotypes exist. In mice, all MCs derive from a common progenitor cell, 
and the protease phenotype of MCs is highly dependent on cytokines and other factors present in 
the microenvironment surrounding the MCs (Kobayashi et al., 1986). In culture and in vivo, single 
CTMC may differentiate into an MMC, and vice versa
 
(Sonoda et al., 1986; Kitamura et al., 1987). 
In addition, MCs with intermediate protease expression have been found (Friend et al., 1996; Friend 
et al., 1998). These observations suggest that mouse MCs retain the ability to reversibly alter their 
protease phenotype as a response to changes in their local microenvironment (Ghildyal et al., 1993; 
Friend et al., 1996; Friend et al., 1998). Changes in the protease phenotype have also been reported 
in human MCs. However, the extent, to which such changes are reversible in individual MCs, is not 
clear. In vitro studies have shown that human MCs, which contain tryptase but little or no chymase, 
may upregulate their chymase expression during incubation with IL-4 and IL-6, resulting in a 
change of the phenotype from MCT to MCTC (Toru et al., 1998; Kinoshita et al., 1999). Depending 
on the source of the progenitor cells such phenotypic switch may require an exceptionally long 
period of culture, even months, as described previously (Kinoshita et al., 1999). This could explain 
the contradictory result previously reported by Irani and coworkers (1992), who did not observe 
phenotypic switch of MCT to MCTC within 30 days. Besides in vitro, MCs are able to upregulate 
chymase also in vivo, as described in patients suffering from pulmonary vascular disease (Hamada 
et al., 1999). Human MCs may also switch their phenotype from MCTC to MCT, as indicated by 
downregulation of chymase expression in MCTC cocultured with human airway epithelial cells 
(Hsieh et al., 2005).  
The exposure of human cord blood-derived MCs to a conditioned medium derived from IL-13-
activated epithelial cells resulted in the downregulation of chymase mRNA, while the mRNA 
expression levels of CPA3 and tryptase remained unaffected (Dougherty et al., 2010). In another 
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study describing gene expression in human tryptase
+
, CPA3
+
, chymase
-
 MCs, CPA3 and tryptase 
mRNAs were upregulated in esophageal samples of patients with eosinophilic esophagitis 
compared with healthy controls, whereas no increase in chymase expression was observed (Abonia 
et al., 2010). These studies provide evidence that the expression of various MC neutral proteases 
may be individually regulated. This hypothesis is further supported by the recent study of granzyme 
B and H expressions in cultured human MCs and LAD2 cells. In these cells, activation by IgE and 
calcium ionophore resulted in upregulation of granzyme B expression, whereas granzyme H 
expression was downregulated, suggesting that these proteases are reciprocally regulated (Rönnberg 
et al., 2014). As the various neutral proteases have distinct substrate specificities, factors that can 
regulate the expression levels of these proteases in MCs will also potentially influence the 
extracellular functions that these cells have after secretion of the proteases.  
The preservation of distinct types of MCs in multiple species implies unique and non-overlapping 
roles for these subtypes. The understanding of functional differences between MCs of various 
phenotypes is limited, however. According to one hypothesis, MCT play a proinflammatory role, 
whereas MCTC specialize in tissue remodeling (McNeil & Gotis-Graham, 2000). This hypothesis is 
supported by the promotion of MCT phenotype by T cells (Irani et al., 1987; Bentley et al., 1996), 
by the accumulation of MCT and MCTC to inflamed and fibrotic tissue areas, respectively (Gotis-
Graham & McNeil, 1997), and by the preferential expression of the inflammation-associated 
protease tryptase by MCT and the extracellular matrix (ECM)–degrading proteases chymase and 
cathepsin G by MCTC (Leskinen et al., 2003; Mäyränpää et al., 2006; Kovanen, 2007; McNeil et al., 
2007). However, not all observations fit into this dichotomy. For instance, tryptase has been 
reported to act on various ECM components or compounds related to ECM turnover (Pejler et al., 
2007), and the potently proinflammatory anaphylatoxin receptor C5aR (CD88) is expressed on 
MCTC, but not on MCT (Oskeritzian et al., 2005). At the moment, limited knowledge exists on the 
functional importance of the two major subtypes of human MCs, not to mention of other human 
MC subtypes with additional protease phenotypes, to permit firm conclusions. Analysis of the 
expressions of the whole variety of MC neutral proteases in MCs isolated from various tissues, both 
normal and diseased, would help clarify the unique roles of MCs with a particular phenotype.  
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7. CONCLUSION 
 
Based on the experimental data of the present Thesis and the current literature, it is suggested that 
all human MCs derive from a common circulating progenitor cell with the potential to express the 
whole variety of human MC neutral proteases. Thus, the protease phenotype of a particular MC 
appears to represent a functional state the MC has assumed under the local microenvironment, and 
is subject to change along with the local microenvironment. Finally, better understanding of the 
factors that regulate MC protease phenotypes is required for a successful design of treatment 
strategies aimed at combatting MC-associated diseases, in which the various proteases released by 
activated MCs contribute to the development and progression of the disease-specific pathologies. 
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